-0.02 (-0.87%)
Symbol SCYX
Price $2.28
Beta 2.141
Volume Avg. 0.40M
Market Cap 84.761M
Shares () -
52 Week Range 1.15-3.87
1y Target Est -
DCF Unlevered SCYX DCF ->
DCF Levered SCYX LDCF ->
ROE 49.42% Strong Buy
ROA 6.67% Neutral
Operating Margin -
Debt / Equity 15.79% Neutral
P/E 4.56 Buy
P/B 1.17 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest SCYX news

Mr. David Gonzalez Angulo M.D.
Drug Manufacturers—Specialty & Generic
NASDAQ Global Market

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.